New Artificial Protein Mimics A Part Of The HIV Outer CoatHealthCanal.comReported during the week of Oct. 21, 2013, in the journal Proceedings of the National Academy of Sciences, the finding provides a potential new strategy in vaccine development to …
|
New artificial protein mimics a part of the HIV outer coat
Science Codex DURHAM, N.C. – A team of scientists at Duke Medicine and Memorial Sloan-Kettering Cancer Center has created an artificial protein coupled with a sugar molecule that mimics a key site on the outer coat of HIV where antibodies can bind to neutralize a … |
|
Rituximab outperformed steroids in Graves’ ophthalmopathy
Healio SAN JUAN, Puerto Rico — Despite data presented earlier at the American Thyroid Association Annual Meeting showing that rituximab was not effective in treating Graves’ ophthalmopathy, another presenter here said that the drug does improve disease state … |
The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells …SBWire (press release)Therapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an average…
|
The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells
PR Carbon (press release) FOR IMMEDIATE RELEASE, Illinois – United States – October 22, 2013 (PR Carbon):Reportstack has announced a new market report on The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells. A comparative analysis and assessment of TCR … |
HPV antibodies may be linked to throat cancerPrivate MDAntibodies from the human papillomavirus may be linked to cases of throat cancer, according to a new study. Blood tests revealed that those with throat cancer are much more likely to have HPV antib…
The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells …PR Newswire (press release)Therapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an av…
|
Roche Holding Ltd. (ADR) (RHHBY): Roche: Impact Of Rituxan Patent Expiration …
Seeking Alpha (click to enlarge) Rituxan (rituximab), MabThera in Europe, is a monoclonal antibody against B-lymphocytes CD20 surface protein used to treat lymphomas, leukemias, transplant rejection and rheumatoid arthritis. Novartis’ Sandoz generics division is on … |
Global and Chinese Monoclonal Antibody Industry Report, 2013GlobeNewswire (press release)In 2011, the sales of six monoclonal antibody agents as Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab …
PharmaStar |
Rituximab, flop nell’oftalmopatia di Graves
PharmaStar Il trattamento con l’anticorpo monoclonale anti-CD20 rituximab non si è rivelato utile nei pazienti con oftalmopatia di Graves (o esoftalmo basedowiano, una forma di esoftalmo che rappresenta una delle principali manifestazioni cliniche del morbo di … |